Treatment‐seeking behavior and cardiovascular morbidity among men with anabolic‐androgenic steroid use: A cross‐sectional study

Author:

Henriksen Hans Christian Bordado12ORCID,Havnes Ingrid Amalia23,Jørstad Marie Lindvik14,Abdullah Rang125,Thorsby Per Medbøe26,Hauger Lisa Evju17,Edvardsen Thor5,Haugaa Kristina H.5,Almaas Vibeke Marie5,Bjørnebekk Astrid1

Affiliation:

1. Anabolic Androgenic Steroid Research Group, Section for Clinical Addiction Research, Division of Mental Health and Addiction Oslo University Hospital Oslo Norway

2. Institute of Clinical Medicine University of Oslo Oslo Norway

3. Division of Mental Health and Addiction Oslo University Hospital Oslo Norway

4. National Advisory Unit on Substance Use Treatment Oslo University Hospital Oslo Norway

5. ProCardio Center for Research Based Innovation, Department of Cardiology, Rikshospitalet Oslo University Hospital Oslo Norway

6. Hormone Laboratory, Department of Medical Biochemistry and Biochemical Endocrinology and Metabolism Research Group Oslo University Hospital Oslo Norway

7. National Centre for Epilepsy, Section for Clinical Psychology and Neuropsychology Oslo University Hospital Oslo Norway

Abstract

AbstractAimsTo determine associations between anabolic‐androgenic steroid (AAS) use‐related morbidity including cardiovascular disease (CVD) and engagement to health services.MethodsIn this cross‐sectional study, 90 males with at least 12 months cumulative current or former use of AAS were included. The participants were divided into a treatment‐seeking group (TSG) and a non‐treatment seeking group (non‐TSG) based on their responses to a self‐report web questionnaire. All participants were screened for symptoms that could be indicative of CVD through a clinical interview, and examined with blood samples, blood pressure measurements and transthoracic echocardiography.ResultsIn the total sample (n = 90), mean age was 39 ± 11 years with cumulative AAS use of 12 ± 9 years. Among men in the TSG with current use there were higher prevalence of dyspnoea (50% vs 7%) and reduced left ventricular ejection fraction (LVEF) in conjunction with left ventricular hypertrophy (LVH) (36 vs. 9%) and/or high blood pressure (55% vs. 19%) compared to men in the non‐TSG. Among men with current AAS use and established LVEF <50% (n = 25) or LVH (n = 21), 44% (11) and 43% (9) respectively, had never engaged health services due to AAS‐related adverse effects. Deviant liver‐ and kidney parameters were frequently observed in the total sample but without between‐group differences.ConclusionsTreatment‐seeking behavior among current AAS users may be associated with increased levels of dyspnoea and established CVD. Despite objective signs of severe CVD among a substantial amount of study participants, it is of great concern that the majority had never sought treatment for AAS‐related concerns.

Funder

Norges Forskningsråd

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3